Group 1 - The company has agreed to acquire 1,623 ordinary shares of China Gene, representing 16.23% of its issued share capital, for a total cash consideration of HKD 43 million [1] - China Gene's main subsidiary, Huaxin, focuses on the research, production, and sales of biopharmaceutical products, particularly in gynecology and gene cell therapy [1] - The acquisition is seen as a strategic investment that will allow the company to expand its market presence in the healthcare and biopharmaceutical sectors in China, which are expected to grow significantly [2][3] Group 2 - The board believes that the acquisition will create potential long-term value and enhance the company's revenue through collaboration in the distribution of China Gene's biopharmaceutical products [2] - China Gene plans to adopt a dividend policy, aiming to distribute at least one-third of its after-tax profits after necessary provisions, which is expected to provide positive financial returns for the company [3] - The company currently has no plans or intentions for further acquisitions of China Gene's shares in the foreseeable future [4]

Core Viewpoint - The company EPS Creation Technology (03860) has agreed to acquire 1,623 shares of China Gene, representing 16.23% of its issued share capital, for a total cash consideration of HKD 43 million, which will be recognized as an investment in an associate in the consolidated financial statements of the group [1] Group 1: Acquisition Details - The acquisition agreement is set to be completed on February 12, 2026, with the total cash consideration being HKD 43 million [1] - Following the completion, the investment in China Gene will be accounted for as an investment in an associate [1] Group 2: Business Synergy and Strategy - The acquisition aligns with the company's existing healthcare product trading, medical device leasing, and CRO services, providing an excellent opportunity to participate in the operations of China Gene, which is experiencing strong growth in the favorable Chinese healthcare and biopharmaceutical market [2] - The company can leverage its extensive sales network in healthcare product trading to assist in the distribution of China Gene's listed biopharmaceutical products, potentially increasing revenue [2] - The integration of the value chain in the healthcare and biopharmaceutical ecosystem is expected to create synergies between the company's HCP and CRO businesses [2] Group 3: Financial Expectations - China Gene plans to adopt a dividend policy, aiming to distribute at least one-third of its after-tax profits after necessary provisions for taxes, loan repayments, and working capital needs [3] - The board anticipates that the investment in China Gene will yield positive financial returns and provide good business opportunities for future development, given its past profitability and dividend policy [3] - The acquisition is viewed as a strategic investment that will enhance the company's market participation in the Chinese healthcare and biopharmaceutical sectors, contributing positively to overall financial performance and long-term growth [3] Group 4: Future Acquisition Plans - The company currently has no plans or intentions for further acquisitions of equity in China Gene in the foreseeable future [4]